[1]王小毛,黄 晶,石 峰.金龙胶囊对耐紫杉醇及卡铂卵巢癌H08910细胞的逆转及增敏作用[J].医学信息,2020,33(04):94-96.[doi:10.3969/j.issn.1006-1959.2020.04.028]
　WANG Xiao-mao,HUANG Jing,SHI Feng.Reversion and Sensitization Effect of Jinlong Capsule on Paclitaxel and Carboplatin-resistant Ovarian Cancer H08910 Cells[J].Medical Information,2020,33(04):94-96.[doi:10.3969/j.issn.1006-1959.2020.04.028]
点击复制

金龙胶囊对耐紫杉醇及卡铂卵巢癌H08910细胞的逆转及增敏作用()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年04期
页码:
94-96
栏目:
论著
出版日期:
2020-02-15

文章信息/Info

Title:
Reversion and Sensitization Effect of Jinlong Capsule on Paclitaxel and Carboplatin-resistant Ovarian Cancer H08910 Cells
文章编号:
1006-1959（2020）04-0094-03
作者:
王小毛; 黄 晶; 石 峰
（1.赣州市肿瘤医院药剂科，江西 赣州 341000；2.赣州市肿瘤医院妇瘤科，江西 赣州 341000；3.赣州市市立医院药剂科，江西 赣州 341000）
Author(s):
WANG Xiao-mao; HUANG Jing; SHI Feng
(1.Department of Pharmacy,Ganzhou Cancer Hospital,Ganzhou 341000,Jiangxi,China;2.Department of Gynecology,Ganzhou Cancer Hospital,Ganzhou 341000,Jiangxi,China;3.Department of Pharmacy,Ganzhou Municipal Hospital,Ganzhou 341000,Jiangxi,China)
关键词:
金龙胶囊; 紫杉醇; 卡铂; 卵巢癌H08910细胞; 逆转; 增敏
Keywords:
Jinlong capsule; Paclitaxel; Carboplatin; Ovarian cancer H08910 cells; Reversal; Sensitization
分类号:
R737.31
DOI:
10.3969/j.issn.1006-1959.2020.04.028
文献标志码:
A
摘要:
目的 探讨金龙胶囊在耐紫杉醇及卡铂卵巢癌H08910细胞的逆转作用及对H08910的致敏活性。方法 测定两种耐药细胞（卵巢癌H08910/Paclitaxel、卵巢癌H08910/Carboplatin）及相应亲本卵巢癌H08910细胞的IC50，并将其与化疗药物组合的无毒浓度的金龙胶囊联用，以XR9576（XR9576为P-gp抑制剂）为阳性对照药，评估不同浓度（80、160、320 μg/ml）的金龙胶囊对耐紫杉醇的卵巢癌细胞、耐卡铂的卵巢癌细胞及交叉耐药的HO8910细胞的逆转活性及增敏作用。结果 金龙胶囊在80、160、320 μg/ml无毒浓度对HO8910/Paclitaxel细胞对紫杉醇的耐药RF倍数分别为1.89、2.48和4.08，但活性弱于阳性对照药；金龙胶囊在80、160、320 μg/ml无毒浓度对HO8910/Paclitaxel细胞对卡铂的交叉耐药有逆转作用。金龙胶囊在80、160、320 μg/ml无毒浓度对HO8910/Carboplatin细胞对紫杉醇的耐药RF倍数分别为1.96、2.16和4.11，但活性弱于阳性对照药；金龙胶囊在80、160、320 μg/ml无毒浓度对HO8910/Carboplatin细胞对卡铂的交叉耐药也有逆转作用。金龙胶囊在80、160、320 μg/ml无毒浓度对HO8910细胞有增敏作用，对Paclitaxel及阳性对照药表现一定量效关系。结论 金龙胶囊对联合化疗的耐药细胞具有耐药逆转的作用，并且对化疗药物具有一定的增敏作用。
Abstract:
Objective To explore the reversal effect of Jinlong capsule on paclitaxel and carboplatin-resistant ovarian cancer H08910 cells and its sensitization activity to H08910.Methods The IC50 of two kinds of drug-resistant cells (ovarian cancer H08910/Paclitaxel, ovarian cancer H08910/Carboplatin) and corresponding parental ovarian cancer H08910 cells were measured, Combined with the non-toxic concentration of Jinlong capsules combined with chemotherapy drugs, XR9576 (XR9576 is a P-gp inhibitor) was used as a positive control drug, and Jinlong capsules of different concentrations (80,160,320 μg/ml) were evaluated. Reversal activity and sensitization of paclitaxel-resistant ovarian cancer cells, carboplatin-resistant ovarian cancer cells, and cross-resistant HO8910 cells.Results Jinlong capsules at 80, 160, and 320 μg/ml non-toxic concentrations of HO8910/Paclitaxel cells resistant to paclitaxel RF folds were 1.89, 2.48, and 4.08, respectively, but the activity was weaker than the positive control drug;Jinlong capsules at 80,160,320 μg/ml non-toxic concentrations can reverse the cross-resistance of HO8910/Paclitaxel cells to carboplatin. Jinlong capsules at 80,160,320 μg/ml non-toxic concentrations of HO8910/Carboplatin cells resistant to paclitaxel RF multiples of 1.96,2.16 and 4.11, respectively, but the activity is weaker than the positive control drug;Jinlong capsule also reversed the cross-resistance of HO8910/Carboplatin cells to carboplatin at non-toxic concentrations of 80, 160 and 320 μg/ml.Jinlong Capsules had a sensitizing effect on HO8910 cells at non-toxic concentrations of 80, 160 and 320 μg/ml, and showed a dose-effect relationship on Paclitaxel and positive control drugs.Conclusion Jinlong Capsule has the effect of reversing drug resistance of drug-resistant cells combined with chemotherapy, and has certain sensitizing effect on chemotherapy drugs.

参考文献/References:

[1]杨欣影.α2，3唾液酸转移酶Ⅲ调节卵巢癌细胞对紫杉醇敏感性的研究[D].暨南大学,2015. [2]曲育莹,岳贵娟,李建生,等.金龙胶囊对耐紫杉醇及长春新碱肿瘤细胞株的逆转及增敏作用[J].肿瘤防治研究,2014,41(8):884-887. [3]李丹,刘延庆.金龙胶囊抗肿瘤的研究进展[J].湖北中医杂志,2018,40(8):59-62. [4]周庆斌,黄喜锋,蒋鹏飞.金龙胶囊联合化疗对胃癌患者生活质量和免疫功能的影响[J].云南中医学院学报,2017,40(6):26-29. [5]刘磊,胡春杰,李志杰,等.水飞蓟宾诱导卵巢癌HO-8910细胞凋亡增殖及其机制探讨[J].现代生物医学进展,2017,17(20):3811-3815. [6]秦贞立,方英姬,黄晓戈.紫杉醇联合卡铂治疗卵巢癌的效果分析[J].实用癌症杂志,2015(2):286-287. [7]张晓前,南志宇.金龙胶囊联合洛铂对非小细胞肺癌肝转移患者疗效及免疫功能调节作用的观察[J].中国药物与临床,2018,18(12):76-77. [8]李旭辉,惠雪枫,王艳梅,等.中药单体逆转肿瘤细胞多药耐药的作用机制[J].延安大学学报(医学科学版),2019(2):96-99. [9]Shi J,Zhang W,He L,et al.Jinlong capsule inhibits migration and invasion in human glioblastoma cells via the modulation of mTOR/S6 signaling pathway[J].Drug Des Devel Ther,2019(13):1023-1032. [10]Zeng C,Cai L,Huang Z,et al.The effect of Jinlong capsule on the immune function for intervened patients with primary liver cancer[J].The Chinese-German Journal of Clinical Oncology,2014,13(2):80-83.

相似文献/References:

[1]李思文,张 燕.不同紫杉醇剂型联合卡铂治疗卵巢癌的疗效研究[J].医学信息,2019,32(07):150.[doi:10.3969/j.issn.1006-1959.2019.07.046]
　LI Si-wen,ZHANG Yan.Therapeutic Effect of Different Paclitaxel Dosage Forms Combined With Carboplatin On Ovarian Cancer[J].Medical Information,2019,32(04):150.[doi:10.3969/j.issn.1006-1959.2019.07.046]
[2]李 博.紫杉醇加顺铂治疗晚期老年非小细胞癌的疗效[J].医学信息,2020,33(10):153.[doi:10.3969/j.issn.1006-1959.2020.10.045]
　LI Bo.Paclitaxel Plus Cisplatin in the Treatment of Advanced Elderly Non-small Cell Carcinoma[J].Medical Information,2020,33(04):153.[doi:10.3969/j.issn.1006-1959.2020.10.045]
[3]葛文军,宋继荣.紫杉醇联合洛铂在局部晚期宫颈癌患者术前新辅助化疗中的应用[J].医学信息,2020,33(13):106.[doi:10.3969/j.issn.1006-1959.2020.13.029]
　GE Wen-jun,SONG Ji-rong.Paclitaxel Combined with Lobaplatin in Neoadjuvant Chemotherapy for Patients with Locally Advanced Cervical Cancer[J].Medical Information,2020,33(04):106.[doi:10.3969/j.issn.1006-1959.2020.13.029]
[4]吴仁瑞,汪 琛,刘 超.紫杉醇联合卡铂方案同步放化疗在Ⅲ期胃食管结合部癌中的近期疗效和安全性[J].医学信息,2022,35(20):52.[doi:10.3969/j.issn.1006-1959.2022.20.012]
　WU Ren-rui,WANG Chen,LIU Chao.Short-term Efficacy and Safety of Concurrent Chemoradiotherapy with Paclitaxel and Carboplatin in Stage Ⅲ Gastroesophageal Junction Cancer[J].Medical Information,2022,35(04):52.[doi:10.3969/j.issn.1006-1959.2022.20.012]
[5]石少庆,宋丽丽.紫杉醇联合卡铂方案在三阴性乳腺癌新辅助化疗中的治疗效果及对患者病理变化的影响[J].医学信息,2023,36(02):145.[doi:10.3969/j.issn.1006-1959.2023.02.031]
　SHI Shao-qing,SONG Li-li.The Therapeutic Effect of Paclitaxel Combined with Carboplatin in Neoadjuvant Chemotherapy for Triple Negative Breast Cancer and its Effect on Pathological Changes[J].Medical Information,2023,36(04):145.[doi:10.3969/j.issn.1006-1959.2023.02.031]

更新日期/Last Update: 2020-02-15